| Melanoma - Drug Pipeline Analysis and Market | | | | restraints and challenges. Each trend is |
| Forecasts to 2015 | | | | independently researched to provide qualitative |
| | | | | analysis of its implications. |
| This is an essential source of information and | | | | - Key topics covered include strategic |
| analysis on the global melanoma disease market. | | | | competitor assessment, market characterization, |
| The report identifies the key trends shaping and | | | | unmet needs and implications for future market |
| driving the global melanoma disease market. The | | | | associated with melanoma. |
| report also provides insight on the prevalent | | | | |
| competitive landscape and the emerging players | | | | Reasons to buy |
| expected to bring significant shift in the market | | | | |
| positioning of the existing market leaders. Most | | | | The report will enhance your decision making |
| importantly, the report provides valuable insight on | | | | capability in a more rapid and time sensitive |
| the pipeline products within the global melanoma | | | | manner. It will allow you to: |
| disease sector. ( ) | | | | - Develop and design your in-licensing and |
| | | | | out-licensing strategies through review of pipeline |
| Scope | | | | products and technologies and by identifying |
| | | | | companies with the most robust pipeline. |
| The scope of the report includes: | | | | - Develop business strategies by understanding |
| - Annualized global melanoma market revenues | | | | the trends shaping and driving the global |
| data from 2000 to 2008, forecast forward for 7 | | | | melanoma disease market. |
| years to 2015. | | | | - Drive revenues by understanding key trends, |
| - Geographies covered in this report include the | | | | innovative products and technologies, market |
| US, the UK, Italy, Spain, Germany, France, and | | | | segments and companies likely to impact the |
| Japan. | | | | global melanoma disease market in future. |
| - Pipeline analysis data providing a split across | | | | - Formulate effective sales and marketing |
| different phases, mechanism of action being | | | | strategies by understanding the competitive |
| developed and emerging trends. Key classes of | | | | landscape and by analyzing the performance of |
| mechanism of action includes oxidative stress | | | | various competitors. |
| inducer targets, Bcl-2 receptor Mitotic Inhibitor, | | | | - Identify emerging players with potentially |
| MAGE antigen, Immunomodulatory effects T-cell | | | | strong product portfolio and create effective |
| enhancer, anti-CTLA4, Peptide Viral vaccine, | | | | counter-strategies to gain competitive advantage. |
| Peptide encapsulated vaccine, Combinations. | | | | - Organize your sales and marketing efforts by |
| - Analysis of the current and future market | | | | identifying the market categories and segments |
| competition in the global melanoma market. Key | | | | that present maximum opportunities for |
| market players covered are Oncolytics Biotech., | | | | consolidations, investments and strategic |
| Bristol-Myers Squibb, Swedish Orphan International | | | | partnerships. |
| AB Bayer Schering Pharma AG, Genta | | | | - What’s the next big thing in the global |
| Incorporated, Schering-Plough, GlaxoSmithKline and | | | | melanoma disease market landscape? – |
| Abraxis BioScience. | | | | Identify, understand and capitalize. |
| - Insightful review of the key industry drivers, | | | | |